PATIENTS
PATIENTS
Clinical Trials
Our clinical trials help to advance the understanding of innovative medicines and determine whether the new treatments being developed are safe and effective.
We know that the decision to participate in clinical trial research is not made lightly, and we sincerely thank all the patients and families who choose to participate. Your physician is the best person to help you decide if a clinical trial or any other treatment option is right for you.
The potential treatments listed below are currently under investigation. Their safety and effectiveness have not yet been established. An investigational drug must be proven safe and effective in clinical trials before it can be approved by the health authorities for prescription use or for use outside of an investigational research study.
Learn more about clinical trials and how they work.
About PROTAC Protein Degraders:
Proteins are molecules that carry out important processes in our cells. However, sometimes certain proteins become damaged or too abundant, which can lead to disease. One of the ways the body naturally targets and eliminates harmful proteins is through the ubiquitin-proteasome system, or UPS. Arvinas is developing a way to make use of this process to destroy disease-causing proteins, called PROTACs. PROTACs have the potential to make use of the body’s natural disposal system to break down proteins that cause different diseases and are currently being studied in clinical trials.
The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.
Vepdegestrant is an investigational oral medicine which is a PROTAC designed to specifically target and degrade the estrogen receptor (ER). Estrogen receptors are proteins that can help promote the growth of certain types of cancer, including breast cancer.
Vepdegestrant is currently undergoing clinical trials to determine how well it works and how safe it is for treating ER-positive/HER2-negative breast cancer.
Vepdegestrant is believed to work by eliminating estrogen receptors, blocking estrogen activity, and potentially stopping tumor growth or causing shrinkage.
Currently Enrolling:
- TACTIVE-U Umbrella Trial: A Study to Learn About the Study Medicine (vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. The TACTIVE-U study is divided into separate sub-studies focused on learning about the side effects and potential benefits of the investigational medicine vepdegestrant when given together with other medicines for potential treatment of advanced or metastatic breast cancer that has worsened after prior treatment.
- Sub-Study A (NCT05548127) will help us learn about the safety and effectiveness of vepdegestrant when taken with the approved breast cancer medicine abemaciclib (a CDK 4/6 inhibitor).
- Sub-Study B (NCT05573555) will help us learn about the safety and effectiveness of vepdegestrant when taken with the approved breast cancer medicine ribociclib (a CDK4/6 inhibitor).
- Sub-Study C (NCT06125522) will help us learn about the safety and effectiveness of vepdegestrant when taken with another medicine, samuraciclib (a CDK7 inhibitor).
- TACTIVE-K: A study to learn about vepdegestrant when given with PF-07220060 to people with advanced or metastatic breast cancer. (NCT0620837).
- This clinical trial can help us learn if the two potential treatments being studied, vepdegestrant and a CDK4 inhibitor (PF-07220060), are safe and effective in people with previously treated advanced or metastatic breast cancer.
If you are interested in learning more about these trials, please speak with your doctor and visit the website www.clinicaltrials.gov by clicking on the trial links above or contact us at +1-475-345-3366 or via email clinicaltrialsARV-471@arvinas.com.
Please note above that NCT refers to the National Clinical Trial number assigned by clinicaltrials.gov.
ARV-393 is an investigational oral medicine which is a PROTAC designed to specifically target and degrade a protein called B-cell lymphoma 6 (BCL6) that is present in many types of non-Hodgkin’s lymphomas and can become damaged or too abundant and promote the growth of certain types of cancer. ARV-393 is currently undergoing clinical trials to determine how well it works and how safe it is for treating non-Hodgkin’s lymphomas.
Currently Enrolling:
- A Phase 1 First-in-Human study of ARV-393 is being conducted on adult participants diagnosed with advanced Non-Hodgkin’s Lymphoma (NHL) (NCT06393738). This clinical trial aims to investigate the safety, and potential activity of the investigational drug ARV-393 in patients with advanced relapsed/refractory non-Hodgkin’s lymphoma.
If you are interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov by clicking on the trial links above or contact us at +1-475-345-3374 or via email at clinicaltrialsARV-393@arvinas.com.
Please note above that NCT refers to the National Clinical Trial number assigned by clinicaltrials.gov.
Luxdegalutamide (ARV-766) is an investigational oral PROTAC designed to specifically target and degrade the androgen receptor (AR), a protein that plays a key role in driving the growth of prostate cancer. In April 2024, Arvinas entered into a global license agreement with Novartis for the development and commercialization of luxdegalutamide for the treatment of prostate cancer. The deal also includes the sale of the AR-V7 program to Novartis. Learn more.